(RTTNews) - Sandoz said that the citrate-free high-concentration formulation or HCF of its biosimilar Hyrimoz (adalimumab-adaz) injection will be available in the United States starting July 1.

The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment, one of the best-selling medicines in the U.S., surged to 36% from just 5% during the first ...

FDA approval of generic pharmaceutical maker Sandoz’s Hyrimoz injection, a biosimilar for Humira, has the potential to “to expand access for millions,” according to a March 21 news release. The ...

Sandoz has obtained the Food and Drug Administration’s blessing for a citrate-free high-concentration formulation of its biosimilar Hyrimoz (adalimumab-adaz) injection. The adalimumab citrate-free HCF ...

Credit: Getty Images. The approval of the new citrate-free, high-concentration formulation was based on data from a phase 1 pharmacokinetics bridging study. The Food and Drug Administration (FDA) has ...

The US Food and Drug Administration has approved a citrate-free, 100 mg/mL formulation of the biosimilar adalimumab-adaz (Hyrimoz), according to a statement from manufacturer Sandoz. Sandoz said that ...

(RTTNews) - Sandoz (SDZNY) has unveiled Hyrimoz or adalimumab citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively ...

The U.S. Food and Drug Administration (FDA) approved Novartis' (NYSE:NVS) citrate-free high-concentration formulation (HCF) of Hyrimoz, a biosimilar to AbbVie's (NYSE:ABBV) blockbuster drug Humira.

(RTTNews) - Sandoz, the generics and biosimilars division of Swiss drug major Novartis AG (NVS), said Monday that the European Commission granted marketing authorization in the European Union for a ...